FG-M131

FG-M131 is an antibody-drug conjugate (ADC) currently under development by FutureGen Biopharmaceutical, specifically targeting peripheral T-cell lymphoma (PTCL). The therapeutic is designed to utilize a monoclonal antibody to selectively bind to an antigen expressed on PTCL cells, delivering a potent cytotoxic payload directly to the tumor site to induce cell death while minimizing systemic toxicity. Although the specific target antigen and the nature of the payload and linker have not been publicly disclosed by the developer, the drug represents a targeted approach to treating aggressive T-cell malignancies within the company's oncology pipeline.